CS MEDICA A/S: Minutes of Extraordinary General Meeting
Today on June 28, 2024, in Copenhagen - CS MEDICA A/S (”CS MEDICA” or “The Company”) held an extraordinary general meeting at which the following principal resolutions were passed.
Authorization for the company's board of directors to list CS MEDICA shares on the German Stock Exchange.
The Extraordinary General Meeting (EGM) resolved in accordance with the Board of Directors’ proposal to authorize the company's board of directors to list the company on one of the multilateral trading facilities (MTF) in Germany.
Authorization for the company's board of directors to list the company's subsidiary, CANNORDIC A/S, on the German Stock Exchange via an initial public offering (IPO) at a valuation of DKK 223.5 million (€30 million). Concurrent proposal to increase the number of shares of CANNORDIC A/S from the current 500 units of DKK 1,000 to 5,000,000 units of DKK 0.1, maintaining the same voting rights.
The EGM resolved, in accordance with the Board of Directors’ proposal, to approve the listing of the company's subsidiary, CANNORDIC A/S, on one of the multilateral trading facilities (MTF) in Germany via an initial public offering (IPO) at a valuation of DKK 223.5 million (€30 million). Concurrently, the EGM approved the proposal to increase the number of shares of CANNORDIC A/S from the current 500 shares with a nominal value of DKK 1,000 each to 5,000,000 shares with a nominal value of DKK 0.10 each, maintaining the same voting rights.
The total number of votes as of the date of this Statement is 12,322,635, whereof 71,8%, equal to 8,842,160, votes were represented at the EGM.
The resolutions were approved unanimously by all shareholders represented at the EGM.
For more information about CS MEDICA, please contact:
Gitte Lund Henriksen, CFO
Phone: + (45) 2774 2280
Email: glh@cs-medica.com
Website: https://www.cs-medica.com/
CS MEDICA A/S, a Danish MedTech pioneer, specializes in developing evidence-based, CBD-integrated treatments for pain management, autoimmune and stress-related disorders. With a focus on patient-centric care, our products range from innovative R&D to registered over-the-counter substance-based medical devices and dermaceuticals. Our flagship CANNASEN® brand, alongside our own-label solutions, exemplifies our dedication to safe, high-quality treatments for both human and veterinary health globally.
The company is listed on Spotlight Stock Market in Stockholm (symbol: “CSMED”). For more information, visit cs-medica.com and LinkedIn.
CANNORDIC A/S, a subsidiary of CS MEDICA Group, is a pioneering MedTech company specializing in innovative substance-based medical devices containing bioactive CBD. Our dedication to enhancing lives by integrating innovation, science, technology, and natural cannabis compounds positions it as a pioneer in the medical technology industry. The company ensures robust research, development, manufacturing, compliance, data insights, and commercialization processes.
Tags: